Arthneeti
Syngene Intl.Q4 FY23

Syngene Intl. Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹402.7P/E: 54.9Market Cap: ₹16.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Syngene Intl. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Syngene Intl. management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Syngene Intl. — get its next earnings analysis in your feed

How does Syngene Intl. rank vs peers in Healthcare Services?

Pro feature
ThisSyngene Intl.
See where Syngene Intl. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Syngene Intl. rank in Healthcare Services?

Compare Syngene Intl. against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Continue your research

What Syngene Intl.'s management said in earlier quarters

Others in Healthcare Services this season

  • Narayana Hrudayalaya Ltd (Q2 FY27)

    Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27

  • Artemis Medicare Services Ltd (Q2 FY27)

    Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service

  • Max Healthcare Institute Ltd (Q2 FY27)

    Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

  • Indegene Ltd (Q2 FY27)

    Revenue from operations for Q2 FY27: INR 11,223 million, up 39.5% YoY (Page 23, 15, 4) . Key investor presentation takeaways from Indegene Ltd's Q2 FY27 investo

Compare:vs Apollo Hospitals Enterprise Ltdvs Manipal Health Enterprises Ltdvs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →